Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
-
- Alina Tscherne
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Jan Hendrik Schwarz
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Cornelius Rohde
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Alexandra Kupke
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Georgia Kalodimou
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Leonard Limpinsel
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Nisreen M. A. Okba
- Department of Viroscience, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands;
-
- Berislav Bošnjak
- Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany;
-
- Inga Sandrock
- Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany;
-
- Ivan Odak
- Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany;
-
- Sandro Halwe
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Lucie Sauerhering
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Katrin Brosinski
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Nan Liangliang
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Elke Duell
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Sylvia Jany
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Astrid Freudenstein
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Jörg Schmidt
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Anke Werner
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Michelle Gellhorn Serra
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Michael Klüver
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Wolfgang Guggemos
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-Universität München, 80804 Munich, Germany;
-
- Michael Seilmaier
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-Universität München, 80804 Munich, Germany;
-
- Clemens-Martin Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-Universität München, 80804 Munich, Germany;
-
- Reinhold Förster
- Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany;
-
- Bart L. Haagmans
- Department of Viroscience, Erasmus Medical Center, 3015 CN Rotterdam, The Netherlands;
-
- Stephan Becker
- Institute of Virology, Philipps University Marburg, 35037 Marburg, Germany;
-
- Gerd Sutter
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
-
- Asisa Volz
- Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, 80539 Munich, Germany;
説明
<jats:title>Significance</jats:title> <jats:p>The highly attenuated vaccinia virus MVA is licensed as smallpox vaccine; as a vector it is a component of the approved adenovirus-MVA–based prime-boost vaccine against Ebola virus disease. Here, we provide results from testing the COVID-19 candidate vaccine MVA-SARS-2-S, a poxvirus-based vector vaccine that proceeded to clinical evaluation. When administered by intramuscular inoculation, MVA-SARS-2-S expresses and safely delivers the full-length SARS-CoV-2 S protein, inducing balanced SARS-CoV-2–specific cellular and humoral immunity, and protective efficacy in vaccinated mice. Substantial clinical experience has been gained with MVA vectors using homologous and heterologous prime-boost applications, including the immunization of children and immunocompromised individuals. Thus, MVA-SARS-2-S represents an important resource for developing further optimized COVID-19 vaccines.</jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 118 (28), e2026207118-, 2021-06-23
Proceedings of the National Academy of Sciences
